ZIOPHARM, Inc. Announces FDA Acceptance of IND for Oral Palifosfamide

NEW YORK, Feb. 6, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for the oral dosing of palifosfamide (Zymafos® or ZIO-201), a form of administration offering several potential patient-oriented advantages and an outpatient treatment for expanded global commercial reach.